{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:36:40Z","timestamp":1791221800571,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1054\/mehy.2000.1128","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T21:52:37Z","timestamp":1027893157000},"page":"114-120","source":"Crossref","is-referenced-by-count":12,"title":["Antidenaturant drugs for cataract and other condensation diseases"],"prefix":"10.1054","volume":"56","author":[{"given":"L.","family":"Saso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1054\/mehy.2000.1128_RF1","first-page":"1911","article-title":"Cataract as a protein condensation disease: the Proctor Lecture","volume":"38","author":"Benedek","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1054\/mehy.2000.1128_RF2","first-page":"165","article-title":"Possible role of a copper complex in the pathogenesis of rheumatoid arthritis","volume":"8","author":"Gerber","year":"1981","journal-title":"Agents Actions Suppl"},{"key":"10.1054\/mehy.2000.1128_RF3","first-page":"439","article-title":"Autoimmune reactions and rheumatoid arthritis","volume":"5","author":"Fehr","year":"1982","journal-title":"Eur J Rheumatol Inflamm"},{"key":"10.1054\/mehy.2000.1128_RF4","first-page":"440","article-title":"Serum and synovial fluid antibodies to collagen in rheumatic diseases: a review","volume":"5","author":"Verbruggen","year":"1986","journal-title":"Clin Rheumatol"},{"key":"10.1054\/mehy.2000.1128_RF5","first-page":"357","article-title":"Free radical denaturation of immunoglobulin G is due to amino acid oxidation: implications for rheumatoid arthritis","volume":"49","author":"Griffiths","year":"1988","journal-title":"Basic Life Sci"},{"key":"10.1054\/mehy.2000.1128_RF6","first-page":"711","article-title":"Inhibitory and disruptive effects of some antirheumatics on antigen-antibody complexes","volume":"33","author":"Kallee","year":"1995","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1054\/mehy.2000.1128_RF7","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.4049\/jimmunol.158.3.1446","article-title":"In patients with rheumatoid arthritis IgG binding to denatured collagen type II is in part mediated by IgG-fibronectin complexes","volume":"158","author":"Mannik","year":"1997","journal-title":"J Immunol"},{"key":"10.1054\/mehy.2000.1128_RF8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1254\/jjp.79.89","article-title":"Inhibition of protein denaturation by fatty acids, bile salts and other natural substances: a new hypothesis for the mechanism of action of fish oil in rheumatic diseases","volume":"79","author":"Saso","year":"1999","journal-title":"Jpn J Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF9","unstructured":"Harding, J. Cataract: Biochemistry, Epidemiology and Pharmacology. London, UK, Chapman and Hall, 1991"},{"key":"10.1054\/mehy.2000.1128_RF10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1994.00001.x","article-title":"Structure and modifications of the junior chaperone \u03b1-crystallin. From lens transparency to molecular pathology","volume":"225","author":"Groenen","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1054\/mehy.2000.1128_RF11","first-page":"1047","article-title":"Cataract as a conformational disease\u2014the Maillard reaction, \u03b1-crystallin and chemotherapy","volume":"44","author":"Crabbe","year":"1998","journal-title":"Cell Mol Biol"},{"key":"10.1054\/mehy.2000.1128_RF12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/302415a0","article-title":"Short-range order of crystallin proteins accounts for eye lens transparency","volume":"302","author":"Delaye","year":"1983","journal-title":"Nature"},{"key":"10.1054\/mehy.2000.1128_RF13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.bb.17.060188.000403","article-title":"Eye lens proteins and transparency: from light transmission theory to solution X-ray structural analysis","volume":"17","author":"Tardieu","year":"1988","journal-title":"Annu Rev Biophys Biophys Chem"},{"key":"10.1054\/mehy.2000.1128_RF14","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/S0006-3495(96)79477-8","article-title":"Structural basis of eye lens transparency: light scattering by concentrated solutions of bovine \u03b1-crystallin proteins","volume":"71","author":"Xia","year":"1996","journal-title":"Biophys J"},{"key":"10.1054\/mehy.2000.1128_RF15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0141-8130(98)00018-X","article-title":"\u03b1-Crystallin quaternary structure and interactive properties control eye lens transparency","volume":"22","author":"Tardieu","year":"1998","journal-title":"Int J Biol Macromol"},{"key":"10.1054\/mehy.2000.1128_RF16","first-page":"423","article-title":"Eye-lens proteins: structure, superstructure, stability, genetics","volume":"81","author":"Jaenicke","year":"1994","journal-title":"Naturwissenschaften"},{"key":"10.1054\/mehy.2000.1128_RF17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1096\/fasebj.10.1.8566552","article-title":"Stability and folding of ultrastable proteins: eye lens crystallins and enzymes from thermophiles","volume":"10","author":"Jaenicke","year":"1996","journal-title":"FASEB J"},{"key":"10.1054\/mehy.2000.1128_RF18","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.1073\/pnas.89.21.10449","article-title":"\u03b1-Crystallin can function as a molecular chaperone","volume":"89","author":"Horwitz","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1054\/mehy.2000.1128_RF19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0141-8130(98)00031-2","article-title":"The possible role of \u03b1-crystallins in human senile cataractogenesis","volume":"22","author":"Takemoto","year":"1998","journal-title":"Int J Biol Macromol"},{"key":"10.1054\/mehy.2000.1128_RF20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1350-9462(98)00030-5","article-title":"\u03b1-Crystallin as a molecular chaperone","volume":"18","author":"Derham","year":"1999","journal-title":"Prog Retin Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00002512-199202040-00003","article-title":"Pharmacological treatment strategies in age-related cataracts","volume":"2","author":"Harding","year":"1992","journal-title":"Drugs Aging"},{"key":"10.1054\/mehy.2000.1128_RF22","first-page":"250","article-title":"Studies on the mechanism of action of bendazac (AF 983)","volume":"20","author":"Silvestrini","year":"1970","journal-title":"Arzneimittelforschung"},{"key":"10.1054\/mehy.2000.1128_RF23","first-page":"217","article-title":"Basic data supporting the use of the l-lysine salt of bendazac in cataract","volume":"5","author":"Silvestrini","year":"1983","journal-title":"Int J Tissue React"},{"key":"10.1054\/mehy.2000.1128_RF24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00003495-199039040-00007","article-title":"Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts","volume":"39","author":"Balfour","year":"1990","journal-title":"Drugs"},{"key":"10.1054\/mehy.2000.1128_RF25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-4835(88)90005-X","article-title":"The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis","volume":"47","author":"Lewis","year":"1988","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF01268125","article-title":"Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac","volume":"90","author":"Marques","year":"1995","journal-title":"Doc Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0014-4835(86)90075-8","article-title":"Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract","volume":"43","author":"Lewis","year":"1986","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF28","first-page":"289","article-title":"Mechanism of the scavenger-like activity of bendazac","volume":"13","author":"Musci","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"10.1054\/mehy.2000.1128_RF29","first-page":"819","article-title":"Studies on the activity of Bendalina (bendazac L-lysine salt) as a scavenger of hydroxyl and superoxide radicals","volume":"97","author":"Schmut","year":"1985","journal-title":"Wien Klin Wochenschr"},{"key":"10.1054\/mehy.2000.1128_RF30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10715768709088097","article-title":"The neutralization of hydroxyl radical by silibin, sorbinil and bendazac","volume":"4","author":"Mira","year":"1987","journal-title":"Free Radic Res Commun"},{"key":"10.1054\/mehy.2000.1128_RF31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0891-5849(90)90004-3","article-title":"Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract","volume":"9","author":"Woollard","year":"1990","journal-title":"Free Radic Biol Med"},{"key":"10.1054\/mehy.2000.1128_RF32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000468888","article-title":"Aldehyde dehydrogenase, aldose reductase, and free radical scavengers in cataract","volume":"45","author":"Crabbe","year":"1991","journal-title":"Enzyme"},{"key":"10.1054\/mehy.2000.1128_RF33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1043-6618(05)80042-8","article-title":"Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent","volume":"32","author":"Guglielmotti","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1054\/mehy.2000.1128_RF34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(82)91893-1","article-title":"Pilot study of bendazac for treatment of cataract","volume":"1","author":"Testa","year":"1982","journal-title":"Lancet"},{"key":"10.1054\/mehy.2000.1128_RF35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jop.1986.2.251","article-title":"Bendazac and benzydamine for treatment of cataract: individualized therapy by the \u201cBLOA test\u201d","volume":"2","author":"Testa","year":"1986","journal-title":"J Ocul Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00142688","article-title":"Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt","volume":"76","author":"Ponte","year":"1990","journal-title":"Doc Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02764301","article-title":"Medical treatment of senile cataract: clinical investigation of bendazac-lysine using objective and subjective methods","volume":"228","author":"Baraldi","year":"1990","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000266799","article-title":"Bendazac lysine in selected types of human senile cataract. A long-term double-masked placebo-controlled clinical trial with multilinear densitometric image analysis of Scheimpflug photographs","volume":"21","author":"Hockwin","year":"1989","journal-title":"Ophthalmic Res"},{"key":"10.1054\/mehy.2000.1128_RF39","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(87)92599-2","article-title":"Hepatotoxicity due to bindazac","volume":"2","author":"Ballesteros","year":"1987","journal-title":"Lancet"},{"key":"10.1054\/mehy.2000.1128_RF40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/00365529609031987","article-title":"Hepatotoxicity due to lysine salt of bendazac","volume":"31","author":"Alcalde","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1054\/mehy.2000.1128_RF41","first-page":"1","article-title":"Inhibition of protein denaturation by antirheumatic or antiphlogistic agents","volume":"149","author":"Mizushima","year":"1964","journal-title":"Arch Intern Pharmacodyn Ther"},{"key":"10.1054\/mehy.2000.1128_RF42","first-page":"115","article-title":"Interaction between plasma proteins and antirheumatic or new antiphlogistic drugs","volume":"157","author":"Mizushima","year":"1965","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1054\/mehy.2000.1128_RF43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0006-2952(70)90234-0","article-title":"Stabilization of serum albumin by anti-inflammatory drugs","volume":"19","author":"Grant","year":"1970","journal-title":"Biochem Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF44","first-page":"918","article-title":"Inhibition of albumin heat denaturation by antiphlogistic-antirheumatic agents","volume":"97","author":"Kalbhen","year":"1972","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1054\/mehy.2000.1128_RF45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0031-6989(76)90046-1","article-title":"Effect of bendazac and phenylbutazone on polymerization of bovine serum albumin","volume":"8","author":"Catanese","year":"1976","journal-title":"Pharmacol Res Commun"},{"key":"10.1054\/mehy.2000.1128_RF46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/CCLM.1998.029","article-title":"Development of and HPLC assay to study the effect of endogenous and exogenous substances on heat-induced aggregation of human serum albumin","volume":"36","author":"Saso","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"10.1054\/mehy.2000.1128_RF47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-4835(90)90226-K","article-title":"Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose","volume":"50","author":"Roberts","year":"1990","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0014-4835(92)90129-G","article-title":"Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen","volume":"54","author":"Blakytny","year":"1992","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00130701","article-title":"Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes","volume":"3","author":"Cotlier","year":"1981","journal-title":"Int Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF50","first-page":"113","article-title":"Senile cataracts: evidence for acceleration by diabetes and deceleration by salicylate","volume":"16","author":"Cotlier","year":"1981","journal-title":"Can J Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF51","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(86)91834-9","article-title":"Do aspirin-like analgesics protect against cataract? A case-control study","volume":"1","author":"van Heyningen","year":"1986","journal-title":"Lancet"},{"key":"10.1054\/mehy.2000.1128_RF52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bjo.72.11.809","article-title":"Drugs, including alcohol, that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide","volume":"72","author":"Harding","year":"1988","journal-title":"Br J Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1755-3768.1989.tb04102.x","article-title":"Protection against cataract by aspirin, paracetamol and ibuprofen","volume":"67","author":"Harding","year":"1989","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1054\/mehy.2000.1128_RF54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archopht.1991.01080020098052","article-title":"Low-dose aspirin and risks of cataract in a randomized trial of US physicians","volume":"109","author":"Seddon","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1076\/opep.5.3.133.8368","article-title":"Low-dose aspirin and risk of cataract and subtypes in a randomized trial of U.S. physicians","volume":"5","author":"Christen","year":"1998","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1054\/mehy.2000.1128_RF56","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archopht.1987.01060090087034","article-title":"Lack of evidence for aspirin use and prevention of cataracts","volume":"105","author":"West","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bjo.76.5.259","volume":"76","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archopht.1992.01080150037023","article-title":"Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16","volume":"110","author":"Chew","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1054\/mehy.2000.1128_RF59","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0161-6420(98)99049-2","article-title":"Medications and cataract. The Blue Mountains Eye Study","volume":"105","author":"Cumming","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1054\/mehy.2000.1128_RF60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0014-4835(85)90014-4","article-title":"Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract","volume":"40","author":"Crompton","year":"1985","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF61","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0006-291X(85)91057-5","article-title":"Acetylation of lens crystallins: a possible mechanism by which aspirin could prevent cataract formation","volume":"128","author":"Rao","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1054\/mehy.2000.1128_RF62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-4835(88)90023-1","article-title":"Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione","volume":"47","author":"Huby","year":"1988","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF63","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0006-291X(88)80463-7","article-title":"Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro.","volume":"151","author":"Rao","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1054\/mehy.2000.1128_RF64","first-page":"1120","article-title":"Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro andin vivo.","volume":"30","author":"Swamy","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1054\/mehy.2000.1128_RF65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-4835(89)90073-0","article-title":"The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione","volume":"49","author":"Ajiboye","year":"1989","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-4835(91)90260-L","article-title":"Non-enzymic modification of lens proteins by glucose and fructose: effects of ibuprofen","volume":"52","author":"Raza","year":"1991","journal-title":"Exp Eye Res"},{"key":"10.1054\/mehy.2000.1128_RF67","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0006-2952(91)90341-2","article-title":"Investigations of ibuprofen and paracetamol binding to lens proteins to explore their protective role against cataract","volume":"42","author":"Shyadehi","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0925-4439(93)90098-L","article-title":"Reaction of aspirin with cysteinyl residues of lens \u03b3-crystallins: a mechanism for the proposed anti-cataract effect of aspirin","volume":"1181","author":"Qin","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1054\/mehy.2000.1128_RF69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-4165(93)90003-Q","article-title":"The reaction of malondialdehyde with lens proteins and the protective effect of aspirin","volume":"1158","author":"Riley","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1054\/mehy.2000.1128_RF70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.115.3.597","article-title":"On the relation of necrosis and inflammation to denaturation of proteins","volume":"115","author":"Opie","year":"1962","journal-title":"J Exp Med"},{"key":"10.1054\/mehy.2000.1128_RF71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1254\/jjp.18.421","article-title":"Inflammatory responses in normal and adrenalectomized rats during obstructive jaundice","volume":"18","author":"Silvestrini","year":"1968","journal-title":"Jpn J Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF72","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"key":"10.1054\/mehy.2000.1128_RF73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9343(84)80020-0","article-title":"Mechanism of action of nonsteroidal anti-inflammatory agents","volume":"77","author":"Goodwin","year":"1984","journal-title":"Am J Med"},{"key":"10.1054\/mehy.2000.1128_RF74","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0306-9877(87)90034-X","article-title":"A review of mechanism of action of aspirin and its potential as an immunomodulating agent","volume":"22","author":"Rumore","year":"1987","journal-title":"Med Hypotheses"},{"key":"10.1054\/mehy.2000.1128_RF75","first-page":"S163","article-title":"The mechanisms of action of nonsteroidal antiinflammatory drugs","volume":"7","author":"Abramson","year":"1989","journal-title":"Clin Exp Rheumatol"},{"key":"10.1054\/mehy.2000.1128_RF76","first-page":"1","article-title":"Neutrophil activation: an alternative to prostaglandin inhibition as the mechanism of action for NSAIDs","volume":"19","author":"Altman","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1054\/mehy.2000.1128_RF77","first-page":"107","article-title":"Mechanisms of action of nonsteroidal anti-inflammatory drugs and therapeutic considerations","volume":"50","author":"Abramson","year":"1990","journal-title":"Bull Hosp Jt Dis Orthop Inst"},{"key":"10.1054\/mehy.2000.1128_RF78","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00002281-199106000-00002","article-title":"Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs","volume":"3","author":"Abramson","year":"1991","journal-title":"Curr Opin Rheumatol"},{"key":"10.1054\/mehy.2000.1128_RF79","first-page":"120","article-title":"The mechanism of action of nonsteroidal antiinflammatory drugs","volume":"27","author":"Brandt","year":"1991","journal-title":"J Rheumatol Suppl"},{"key":"10.1054\/mehy.2000.1128_RF80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0167-5699(97)01216-4","article-title":"Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs","volume":"19","author":"Diaz-Gonzalez","year":"1998","journal-title":"Immunol Today"},{"key":"10.1054\/mehy.2000.1128_RF81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01982638","article-title":"Animal models for the study of atypical anti-inflammatory agents","volume":"17","author":"Silvestrini","year":"1986","journal-title":"Agents Actions"},{"key":"10.1054\/mehy.2000.1128_RF82","first-page":"1735","article-title":"A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats","volume":"19","author":"Cioli","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1054\/mehy.2000.1128_RF83","first-page":"747","article-title":"Chronic inflammatory response in the rat can be blocked by bindarit","volume":"29","author":"Guglielmotti","year":"1993","journal-title":"Biochem Mol Biol Int"},{"key":"10.1054\/mehy.2000.1128_RF84","first-page":"1859","article-title":"Abnormal glycosylation of hemopexin in arthritic rats can be blocked by bindarit","volume":"19","author":"Saso","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1054\/mehy.2000.1128_RF85","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00918999","article-title":"Changes of immunoreactivity in \u03b11-antitrypsin in patients with autoimmune diseases","volume":"17","author":"Saso","year":"1993","journal-title":"Inflammation"},{"key":"10.1054\/mehy.2000.1128_RF86","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00916586","article-title":"Abnormal glycosylation of \u03b12-macroglobulin, a non-acute-phase protein in patients with autoimmune diseases","volume":"17","author":"Saso","year":"1993","journal-title":"Inflammation"},{"key":"10.1054\/mehy.2000.1128_RF87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0009-9120(99)00010-7","article-title":"Development of an enzyme-linked immunosorbent assay, using a monoclonal antibody against \u03b12-macroglobulin, for the diagnosis of systemic lupus erythematosus","volume":"32","author":"Cazzolla","year":"1999","journal-title":"Clin Biochem"},{"key":"10.1054\/mehy.2000.1128_RF88","first-page":"149","article-title":"Bindarit prolongs survival and reduces renal damage in NZB\/W lupus mice","volume":"16","author":"Guglielmotti","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1054\/mehy.2000.1128_RF89","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1046\/j.1523-1755.1998.00804.x","article-title":"Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease","volume":"53","author":"Zoja","year":"1998","journal-title":"Kidney Int"},{"key":"10.1054\/mehy.2000.1128_RF90","first-page":"11","volume":"11","year":"1999","journal-title":"Drug Benefit Trends"},{"key":"10.1054\/mehy.2000.1128_RF91","unstructured":"Anonymous. FDA awards 28 grants for orphan product research. 1998"},{"key":"10.1054\/mehy.2000.1128_RF92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/art.1780170113","article-title":"Copper-catalyzed thermal aggregation of human gamma-globulin. Inhibition by histidine, gold thiomalate, and penicillamine","volume":"17","author":"Gerber","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1054\/mehy.2000.1128_RF93","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0006-2952(78)90378-7","article-title":"Inhibition of the denaturation of human \u03b3-globulin by a mixture of D-penicillamine disulfide and copper. A possible mechanism of action of D-penicillamine in rheumatoid arthritis","volume":"27","author":"Gerber","year":"1978","journal-title":"Biochem Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF94","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1254\/fpj.74.193","article-title":"Studies on D-penicillamine (1): Inhibitory effect of D-penicillamine on the heat-Cu++induced denaturation of human \u03b3-globulin","volume":"74","author":"Otomo","year":"1978","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"10.1054\/mehy.2000.1128_RF95","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/art.1780190311","article-title":"Inhibition of denaturation of human \u03b3-globulin by a mixture of L-histidine, L-cystine, and copper, and its clinical implication in rheumatoid arthritis","volume":"19","author":"Gerber","year":"1976","journal-title":"Arthritis Rheum"},{"key":"10.1054\/mehy.2000.1128_RF96","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-3011.1976.tb02478.x","article-title":"Heat denaturation of human serum albumin. Migration of bound fatty acids","volume":"8","author":"Brandt","year":"1976","journal-title":"Int J Pept Protein Res"},{"key":"10.1054\/mehy.2000.1128_RF97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60065-0","article-title":"Serum albumin","volume":"37","author":"Peters","year":"1985","journal-title":"Adv Protein Chem"},{"key":"10.1054\/mehy.2000.1128_RF98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-3233(08)60640-3","article-title":"Structure of serum albumin","volume":"45","author":"Carter","year":"1994","journal-title":"Adv Protein Chem"},{"key":"10.1054\/mehy.2000.1128_RF99","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1432-1033.1995.tb20425.x","article-title":"Fatty acid binding to bovine serum albumin prevents formation of intermediate during denaturation","volume":"227","author":"Ahmad","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1054\/mehy.2000.1128_RF100","unstructured":"Coe, F. L. Favus, M. J. Pak, C. Y. C. Parks, J. H. Preminger, G. M. Kidney stones, medical and surgical management. Philadelphia, PA, Lippincott-Raven, 1996"},{"key":"10.1054\/mehy.2000.1128_RF101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0022-5347(17)66686-2","article-title":"The amount and nature of organic matrix in urinary calculi: a review","volume":"76","author":"Boyce","year":"1956","journal-title":"J Urol"},{"key":"10.1054\/mehy.2000.1128_RF102","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0022-5347(17)42541-9","article-title":"Urinary stone matrix","volume":"139","author":"Morse","year":"1988","journal-title":"J Urol"},{"key":"10.1054\/mehy.2000.1128_RF103","series-title":"Kidney stones, medical and surgical management","article-title":"Nucleation, growth and aggregation of stone-forming crystals","author":"Hess","year":"1996"},{"key":"10.1054\/mehy.2000.1128_RF104","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(79)92755-7","article-title":"Uromucoids and urinary stone formation","volume":"1","author":"Hallson","year":"1979","journal-title":"Lancet"},{"key":"10.1054\/mehy.2000.1128_RF105","series-title":"Kidney stones, medical and surgical management","article-title":"Urinary inhibitors and renal stone formation","author":"Lieske","year":"1996"},{"key":"10.1054\/mehy.2000.1128_RF106","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s004670050185","article-title":"Glycosaminoglycans, proteins, and stone formation: adult themes and child\u2019s play","volume":"10","author":"Ryall","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"10.1054\/mehy.2000.1128_RF107","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000030214","article-title":"Urinary kidney stone inhibitors. What is the news?","volume":"60","author":"Dussol","year":"1998","journal-title":"Urol Int"},{"key":"10.1054\/mehy.2000.1128_RF108","first-page":"1019","article-title":"Calcium oxalate crystal growth in the presence of mucin","volume":"5","author":"Akbarieh","year":"1991","journal-title":"Scanning Microsc"},{"key":"10.1054\/mehy.2000.1128_RF109","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.1992.tb15724.x","article-title":"Agglomeration of calcium oxalate monohydrate in synthetic urine","volume":"70","author":"Grases","year":"1992","journal-title":"Br J Urol"},{"key":"10.1054\/mehy.2000.1128_RF110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2302\/kjm.46.1","article-title":"Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion","volume":"46","author":"Nakagawa","year":"1997","journal-title":"Keio J Med"},{"key":"10.1054\/mehy.2000.1128_RF111","first-page":"393","article-title":"Tamm-Horsfall glycoprotein and calcium nephrolithiasis","volume":"20","author":"Hess","year":"1994","journal-title":"Miner Electrolyte Metab"},{"key":"10.1054\/mehy.2000.1128_RF112","first-page":"371","article-title":"Citrate and renal calculi: an update","volume":"20","author":"Pak","year":"1994","journal-title":"Miner Electrolyte Metab"},{"key":"10.1054\/mehy.2000.1128_RF113","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00182052","article-title":"Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate","volume":"12","author":"Fellstrom","year":"1994","journal-title":"World J Urol"},{"key":"10.1054\/mehy.2000.1128_RF114","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.1994.tb16612.x","article-title":"The role of Tamm-Horsfall mucoprotein in calcium oxalate crystallization. N-acetylcysteine \u2013 a new therapy for calcium oxalate urolithiasis","volume":"74","author":"Fan","year":"1994","journal-title":"Br J Urol"},{"key":"10.1054\/mehy.2000.1128_RF115","first-page":"379","article-title":"Pathogenesis of gallstones","volume":"83","author":"Carey","year":"1992","journal-title":"Recenti Prog Med"},{"key":"10.1054\/mehy.2000.1128_RF116","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1172\/JCI111204","article-title":"Biliary proteins. Unique inhibitors of cholesterol crystal nucleation in human gallbladder bile","volume":"73","author":"Holzbach","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1054\/mehy.2000.1128_RF117","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1126\/science.6429856","article-title":"Inhibition of cholesterol crystal formation by apolipoproteins in supersaturated model bile","volume":"225","author":"Kibe","year":"1984","journal-title":"Science"},{"key":"10.1054\/mehy.2000.1128_RF118","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1172\/JCI114389","article-title":"Isolation of an acidic protein from cholesterol gallstones, which inhibits the precipitation of calcium carbonate in vitro.","volume":"84","author":"Shimizu","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1054\/mehy.2000.1128_RF119","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-2275(20)42057-7","article-title":"Inhibition and promotion of cholesterol crystallization by protein fractions from normal human gallbladder bile","volume":"32","author":"Busch","year":"1991","journal-title":"J Lipid Res"},{"key":"10.1054\/mehy.2000.1128_RF120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0016-5085(93)90423-A","article-title":"Isolation of a human biliary glycoprotein inhibitor of cholesterol crystallization","volume":"104","author":"Ohya","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1054\/mehy.2000.1128_RF121","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0022-2143(96)90075-X","article-title":"Purification and characterization of a novel human 15 kd cholesterol crystallization inhibitor protein in bile","volume":"127","author":"Secknus","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1054\/mehy.2000.1128_RF122","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1440-1746.1999.01881.x","article-title":"Apolipoprotein A-I in bile inhibits cholesterol crystallization and modifies transcellular lipid transfer through cultured human gall-bladder epithelial cells","volume":"14","author":"Secknus","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1054\/mehy.2000.1128_RF123","first-page":"60","article-title":"An update on the pathogenesis and treatment of cholesterol gallstones","volume":"223","author":"Portincasa","year":"1997","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1054\/mehy.2000.1128_RF124","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0889-8553(05)70045-5","article-title":"Gallstone formation. Local factors","volume":"28","author":"Ko","year":"1999","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1054\/mehy.2000.1128_RF125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0002-9610(83)90166-6","article-title":"Role of gallbladder mucus in the pathogenesis of cholesterol gallstones","volume":"145","author":"Doty","year":"1983","journal-title":"Am J Surg"},{"key":"10.1054\/mehy.2000.1128_RF126","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1002\/hep.1840040809","article-title":"Role of gallbladder mucin in pathophysiology of gallstones","volume":"4","author":"LaMont","year":"1984","journal-title":"Hepatology"},{"key":"10.1054\/mehy.2000.1128_RF127","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02470708","article-title":"The pathophysiological characteristics of bile from patients with gallstones: the role of prostaglandins and mucin in gallstone formation","volume":"20","author":"Inoue","year":"1990","journal-title":"Jpn J Surg"},{"key":"10.1054\/mehy.2000.1128_RF128","first-page":"183S","article-title":"Gallbladder mucin as a pronucleating agent for cholesterol monohydrate crystals in bile","volume":"12","author":"Smith","year":"1990","journal-title":"Hepatology"},{"key":"10.1054\/mehy.2000.1128_RF129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000199410","article-title":"Mucus glycoprotein content of human cholesterol gallstones","volume":"36","author":"Pearson","year":"1987","journal-title":"Digestion"},{"key":"10.1054\/mehy.2000.1128_RF130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00365527109180669","article-title":"Anti-inflammatory drugs and gastric mucus","volume":"6","author":"Johansson","year":"1971","journal-title":"Scand J Gastroenterol"},{"key":"10.1054\/mehy.2000.1128_RF131","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0006-2952(78)90412-4","article-title":"The effects of aspirin and other non-steroid anti-inflammatory\/analgesic drugs on gastro-intestinal mucus glycoprotein biosynthesis in vivo: relationship to ulcerogenic actions","volume":"27","author":"Rainsford","year":"1978","journal-title":"Biochem Pharmacol"},{"key":"10.1054\/mehy.2000.1128_RF132","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0889-8553(05)70247-8","article-title":"NSAIDs, gastrointestinal injury, and cytoprotection","volume":"25","author":"Scheiman","year":"1996","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1054\/mehy.2000.1128_RF133","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(88)90812-4","article-title":"Prevention of gallstone recurrence by non-steroidal anti-inflammatory drugs","volume":"2","author":"Hood","year":"1988","journal-title":"Lancet"},{"key":"10.1054\/mehy.2000.1128_RF134","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.7466399","article-title":"Aspirin prevention of cholesterol gallstone formation in prairie dogs","volume":"211","author":"Lee","year":"1981","journal-title":"Science"},{"key":"10.1054\/mehy.2000.1128_RF135","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/BF01297455","article-title":"One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease","volume":"36","author":"Kurata","year":"1991","journal-title":"Dig Dis Sci"},{"key":"10.1054\/mehy.2000.1128_RF136","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/00365529409094849","article-title":"Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy?","volume":"29","author":"Adamek","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"10.1054\/mehy.2000.1128_RF137","first-page":"514","article-title":"Effect of non-steroidal anti-inflammatory drugs on formation of gallbladder stones","volume":"36","author":"Minocha","year":"1994","journal-title":"Vet Hum Toxicol"},{"key":"10.1054\/mehy.2000.1128_RF138","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1572-0241.1998.00453.x","article-title":"Nonsteroidal antiinflammatory drug use and gallstone disease prevalence: a case-control study","volume":"93","author":"Pazzi","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1054\/mehy.2000.1128_RF139","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/cs0860075","article-title":"Heterogeneity of human biliary mucin: functional implications","volume":"86","author":"Klinkspoor","year":"1994","journal-title":"Clin Sci (Colch)"},{"key":"10.1054\/mehy.2000.1128_RF140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/cs0860067","article-title":"Heterogeneity of human gallbladder mucin in bile","volume":"86","author":"van Wijland","year":"1994","journal-title":"Clin Sci (Colch)"},{"key":"10.1054\/mehy.2000.1128_RF141","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0039-6060(05)80368-X","article-title":"Dietary fish oil inhibits cholesterol monohydrate crystal nucleation and gallstone formation in the prairie dog","volume":"118","author":"Magnuson","year":"1995","journal-title":"Surgery"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987700911289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987700911289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T23:36:15Z","timestamp":1682292975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987700911289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["S0306987700911289"],"URL":"https:\/\/doi.org\/10.1054\/mehy.2000.1128","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}